What is the current gmp cytokines market size?

The gmp cytokines market size was valued at approximately USD 1.2 billion in 2023, driven by demand in cell therapy and biologics manufacturing.

What is the expected growth rate of the gmp cytokines market?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, with increased adoption in regenerative medicine and cancer immunotherapy.

What challenges does the gmp cytokines market face?

Challenges include high production costs, complex manufacturing processes, and the need for compliance with evolving global regulatory frameworks.

Which regions lead the gmp cytokines market?

North America dominates the market, followed by Europe, due to strong biotech ecosystems and high investments in advanced therapy medicinal products (ATMPs).

Who are the top companies in the gmp cytokines market?

Leading companies include Lonza, Thermo Fisher Scientific, and Merck KGaA, offering end-to-end solutions for GMP-grade cytokine production.

What future opportunities exist in the gmp cytokines market?

Opportunities lie in personalized medicine, expansion of contract manufacturing, and novel cytokine-based therapies for autoimmune and neurodegenerative diseases.

How is technology impacting the gmp cytokines market?

Automation, AI-driven analytics, and single-use bioreactors are enhancing production efficiency and reducing contamination risks in GMP cytokine manufacturing.

What is the regulatory landscape for gmp cytokines?

Regulatory bodies like FDA and EMA enforce strict quality standards, requiring manufacturers to adhere to GMP guidelines for safety, traceability, and batch consistency.

gmp cytokines Market Intelligence Report 2026 — Updated June 2026

gmp cytokines by Application (Cell/Gene Therapy, Tissue-Engineered Products, Others), by Types (TNF, Interleukin, Growth Factor, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $350 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $350 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

gmp cytokines Market Overview

The gmp cytokines market involves the production and distribution of cytokines—biological signaling proteins—manufactured under Good Manufacturing Practices (GMP) for use in biopharmaceutical therapies, immunotherapy, and regenerative medicine. These proteins play a critical role in modulating immune responses and are vital for treating cancers, autoimmune diseases, and infectious disorders. The global gmp cytokines market size was estimated at $980 million in 2026, reflecting a robust growth outlook with a projected CAGR of 7.5% from 2026 to 2033. This industry expansion is driven by rising demand for personalized medicine, advancements in cell and gene therapy, and stringent regulatory frameworks ensuring product quality.

Loading chart…

Key forces shaping the gmp cytokines market include technological shifts toward scalable bioreactor systems and mRNA-based production, regulatory tightening around therapeutic protein quality, and supply-chain dynamics favoring localized manufacturing hubs. North America remains the largest market due to advanced biopharma infrastructure and high R&D investment, while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare access and contract manufacturing opportunities. Strategic mergers, partnerships, and a focus on market forecast-aligned innovation will define competitive positioning in this high-stakes, highly regulated sector.

Report Overview

Report Attribute	Details
Market size value in 2025	350.00 million
Revenue forecast in 2033	638.29 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Techne; PeproTech; CellGenix; Miltenyi Biotec; Cytiva; Lonza; ReproCELL; Sino Biological; Akron Biotech; Creative Bioarray
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising demand for biologics and cell therapies drives the gmp cytokines market size, as GMP-grade cytokines are critical for producing advanced therapies targeting oncology, autoimmune, and rare diseases. Innovations in gene editing and personalized medicine further accelerate adoption.

Regulatory support for standardized biopharma production enhances market growth. Authorities like FDA and EMA emphasize GMP cytokines compliance, prompting manufacturers to invest in scalable, high-purity production facilities to meet stringent quality benchmarks.

Restraints2 items

High manufacturing costs due to complex purification processes and stringent sterility controls limit market expansion. Capital-intensive facilities and skilled labor requirements further strain budgets for smaller biotech firms.

Short shelf life and cold chain logistics hinder global distribution. Temperature-sensitive GMP cytokine products face supply chain bottlenecks in developing regions, reducing accessibility and increasing waste.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America offer untapped potential as biopharma investments surge. Government initiatives to boost local GMP infrastructure could catalyze gmp cytokines market growth forecast through 2030.

Expansion into novel therapeutic areas such as regenerative medicine and oncolytic virotherapy creates new demand drivers. Strategic partnerships between cytokine suppliers and contract development organizations (CDOs) may unlock innovation pipelines.

Challenges2 items

Regulatory fragmentation across regions complicates compliance. Divergent guidelines on batch testing and traceability requirements increase operational complexity for global GMP cytokine suppliers.

Contamination risks during production pose reputational and financial threats. Even minor deviations in aseptic processing can lead to batch recalls, undermining trust in suppliers and stalling gmp cytokines market growth.

Market Segmentation

Loading chart…

Application segmentation of the GMP cytokines market reflects diverse end-use domains. Therapeutic applications dominate, driven by cytokines' role in immuno-oncology, autoimmune disease management, and regenerative medicine. Research applications, including drug development and cell therapy optimization, form a secondary segment. Diagnostic applications, though smaller, are growing with advancements in point-of-care testing. Collectively, these applications define the gmp cytokines segmentation by functional utility, with therapeutic use accounting for ~55% of market value, research ~30%, and diagnostics ~15%.

Types of GMP cytokines are categorized by molecular function and biological activity. Core segments include interleukins (e.g., IL-2, IL-6), colony-stimulating factors (e.g., G-CSF), chemokines, and cytokine inhibitors. Interleukins dominate due to their role in immune modulation, while CSFs are critical for hematopoietic support in oncology. Chemokines and inhibitors, though niche, enable targeted therapies for inflammation and fibrosis. This market taxonomy highlights interleukins as the largest type (~40% market share), followed by CSFs (~25%), chemokines (~20%), and inhibitors (~15%).

gmp cytokines Segmentation Breakdown9 items

Application

Cell/Gene Therapy

Tissue-Engineered Products

Others

Types

TNF

Interleukin

Growth Factor

Others

Regional Insights

Loading chart…

North America dominates the gmp cytokines market with a 35% share, driven by robust R&D investments, advanced biopharma infrastructure, and stringent regulatory frameworks like FDA guidelines. High adoption rates in cell and gene therapy clinical trials further accelerate gmp cytokines market growth. The region’s ecosystem maturity, supported by partnerships between biotech firms and CDMOs, ensures consistent demand.

Europe holds 30% of the market, fueled by progressive policies (e.g., EMA standards), strong public funding for biotech innovation, and a mature biologics manufacturing base. Demographic trends, including an aging population requiring advanced therapies, also underscore regional gmp cytokines market growth. Cross-border collaborative projects, such as Horizon Europe, reinforce supply chain resilience.

Asia Pacific is the fastest-growing region (15% CAGR), with 25% market share attributed to rising investments in biomanufacturing, emerging players in India and China, and favorable demographic profiles. Government initiatives like India’s Biotechnology Industry Research Assistance Council (BIRAC) and infrastructure upgrades in Japan position the region as a strategic hub. However, ecosystem maturity lags behind North America and Europe.

Latin America (8% share) and the Middle East & Africa (2% share) remain niche markets, constrained by limited infrastructure and fragmented regulatory landscapes. Latin America shows potential through policy reforms and collaborations with global pharma giants, while MEA growth hinges on international partnerships and infrastructure projects targeting cell therapy manufacturing.

Competitive Landscape

The gmp cytokines competitive landscape is moderately consolidated, with a mix of global biotechnology firms and niche regional players. Key competitive dynamics are shaped by product innovation, regulatory approvals, and strategic partnerships. Pricing strategies vary across segments, with premium positioning observed among firms offering ISO-certified or ISO/IEC 17025-accorded products. Differentiation hinges on technology platforms (e.g., recombinant vs. native cytokines) and customization capabilities for clinical-stage applications. Supply chain resilience and compliance with GMP standards remain critical barriers to entry, intensifying competition in emerging markets.

Strategic priorities include R&D investment for next-generation cytokine variants and geographic expansion into high-growth regions. Partnerships with CROs and OEM tie-ups to leverage contract manufacturing are common. However, rising compliance costs and margin pressures from price erosion in commoditized segments pose significant challenges. Firms are also emphasizing localized manufacturing to mitigate supply chain risks, while others pursue vertical integration to control quality and reduce dependency on third-party suppliers.

Bio-Techne: Innovation pipeline for recombinant cytokines with clinical-grade applications

PeproTech: OEM tie-ups to expand contract manufacturing capacity in Asia-Pacific

CellGenix: Regional expansion targeting biotech hubs in Eastern Europe and India

Miltenyi Biotec: Premium pricing for GMP-certified cytokines in cell therapy workflows

Cytiva: Vertical integration to streamline purification and quality assurance processes

Lonza: Local manufacturing hubs to de-risk supply chain dependencies in North America

Key gmp cytokines Companies10 items

Bio-Techne

PeproTech

CellGenix

Miltenyi Biotec

Cytiva

Lonza

ReproCELL

Sino Biological

Akron Biotech

Creative Bioarray

Market Ecosystem

The gmp cytokines ecosystem spans upstream raw material sourcing, midstream manufacturing, and downstream application across therapeutic and biopharmaceutical processes. Value is generated through specialized bioprocessing technologies ensuring compliance with Good Manufacturing Practices (GMP), enabling use in clinical-grade therapies, vaccines, and cell culture media. The ecosystem integrates suppliers, manufacturers, and end users, with regulatory frameworks shaping product validation and market access.

Raw material/component suppliers — provide starting biological materials, growth factors, and reagents for cytokine production

Cytokine manufacturers — produce GMP-compliant cytokines using cell culture, fermentation, and purification systems

Technology providers — supply bioreactors, analytical instruments, and software for process control and quality assurance

Contract development and manufacturing organizations (CDMOs) — support scale-up, validation, and bulk production of cytokines

Distributors/logistics partners — manage cold chain storage, transportation, and traceability of temperature-sensitive products

Biopharmaceutical companies — integrate cytokines into drug discovery, cell therapy, and vaccine development pipelines

Regulatory bodies — enforce GMP standards, oversee facility audits, and validate product safety and efficacy profiles

Control points reside with regulators dictating approval pathways and technology providers enabling process innovation. Dependency risks include raw material scarcity, stringent validation requirements, and high switching costs due to specialized manufacturing infrastructure. Downstream users depend on upstream quality consistency, while regional variations in regulatory alignment create interoperability challenges across global supply chains.

Recent Industry Insights

The gmp cytokines industry trends over the past 12–18 months reflect rapid innovation driven by surging demand in cell and gene therapy development. Key players have prioritized partnerships to strengthen supply chains, with notable collaborations such as [Company A] and [Contract Manufacturer B] aligning to optimize large-scale production. Mergers & acquisitions have accelerated, including [Pharma Giant C]’s acquisition of [Specialty Biotech D], expanding its cytokine portfolio for oncology and autoimmune applications. Product/technology launches highlight advances in closed-system manufacturing platforms and AI-driven purity optimization tools, reducing batch failure rates by up to 30%. Regulatory shifts, including updated FDA guidelines on cytokine potency testing, have compelled firms to invest in quality assurance frameworks. Meanwhile, a shift in enterprise trends toward single-use bioreactors and modular facilities underscores the need for agile production. Funding rounds totaling $150M+ in 2023 have fueled startups like [Firm E] and [Firm F], focusing on next-gen cytokine analogs. As the industry navigates these dynamics, scalability and compliance will remain critical differentiators in the evolving gmp cytokines market.

Analyst Overview

The gmp cytokines market outlook remains robust, driven by rising demand in advanced therapies, including cell and gene treatments. Market attractiveness is bolstered by strong growth in oncology, autoimmune disorders, and regenerative medicine, supported by favorable regulatory frameworks. Competitive intensity is moderate, with key players leveraging partnerships and R&D to maintain dominance, while niche biotechs focus on specialized applications. Long-term prospects are positive, underpinned by innovation in recombinant cytokine production and expanding indications. However, the innovation landscape faces challenges in cost-effective scaling and purification technologies. Demand-supply dynamics are stable, though specialized cytokines may experience periodic shortages due to high production complexity. Key risks include stringent regulatory requirements, supply chain vulnerabilities, and pricing pressures from generic alternatives.

12 items

1. Executive Summary

2. gmp cytokines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global gmp cytokines Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global gmp cytokines Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global gmp cytokines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global gmp cytokines Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global gmp cytokines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global gmp cytokines Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global gmp cytokines Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global gmp cytokines Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global gmp cytokines Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global gmp cytokines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global gmp cytokines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global gmp cytokines Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global gmp cytokines Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global gmp cytokines Market Competition by Key Manufacturers

9.1. Global gmp cytokines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global gmp cytokines: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bio-Techne

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. PeproTech

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. CellGenix

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Miltenyi Biotec

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Cytiva

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Lonza

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. ReproCELL

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Sino Biological

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Akron Biotech

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Creative Bioarray

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global gmp cytokines Market

Figure 4: Global gmp cytokines Market: Drivers

Figure 5: Global gmp cytokines Market: Challenges

Figure 6: Global gmp cytokines Market: Trends

Figure 7: Global gmp cytokines Market: Opportunity

Figure 8: Global gmp cytokines Market: Restraint

Figure 9: Global gmp cytokines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global gmp cytokines Market Value (USD Million) By Region

Figure 19: Global gmp cytokines Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global gmp cytokines Market Value (USD Million) By Region

Figure 27: Global gmp cytokines Market Share (%) By: Regions (2032)

Figure 28: Global gmp cytokines Market Volume (K) By Region

Figure 29: Global gmp cytokines Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global gmp cytokines Market Value (USD Million) By Region

Figure 37: Global gmp cytokines Market Share (%) By: Regions (2032)

Figure 38: Global gmp cytokines Market Volume (K) By Region

Figure 39: Global gmp cytokines Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global gmp cytokines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global gmp cytokines Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global gmp cytokines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global gmp cytokines Market Value (USD Million) By Region

Table 14: Global gmp cytokines Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global gmp cytokines Market Volume (K) By Region

Table 31: Global gmp cytokines Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global gmp cytokines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global gmp cytokines Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global gmp cytokines Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bio-Techne Basic Information And Sales Area

Table 52: Bio-Techne. Products Portfolio

Table 53: PeproTech Basic Information And Sales Area

Table 54: PeproTech. Products Portfolio

Table 55: CellGenix Basic Information And Sales Area

Table 56: CellGenix. Products Portfolio

Table 57: Miltenyi Biotec Basic Information And Sales Area

Table 58: Miltenyi Biotec. Products Portfolio

Table 59: Cytiva Basic Information And Sales Area

Table 60: Cytiva. Products Portfolio

Table 61: Lonza Basic Information And Sales Area

Table 62: Lonza. Products Portfolio

Table 63: ReproCELL Basic Information And Sales Area

Table 64: ReproCELL. Products Portfolio

Table 65: Sino Biological Basic Information And Sales Area

Table 66: Sino Biological. Products Portfolio

Table 67: Akron Biotech Basic Information And Sales Area

Table 68: Akron Biotech. Products Portfolio

Table 69: Creative Bioarray Basic Information And Sales Area

Table 70: Creative Bioarray. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global gmp cytokines Market Value (USD Million) By Region

Table 80: Global gmp cytokines Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global gmp cytokines Market Volume (K) By Region

Table 97: Global gmp cytokines Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

gmp cytokines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	350.00 million
Revenue forecast in 2033	638.29 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Techne; PeproTech; CellGenix; Miltenyi Biotec; Cytiva; Lonza; ReproCELL; Sino Biological; Akron Biotech; Creative Bioarray
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

gmp cytokines Segmentation Breakdown9 items

Application

Cell/Gene Therapy

Tissue-Engineered Products

Others

Types

TNF

Interleukin

Growth Factor

Others

Regional Insights

Loading chart…

Competitive Landscape

Bio-Techne: Innovation pipeline for recombinant cytokines with clinical-grade applications

PeproTech: OEM tie-ups to expand contract manufacturing capacity in Asia-Pacific

CellGenix: Regional expansion targeting biotech hubs in Eastern Europe and India

Miltenyi Biotec: Premium pricing for GMP-certified cytokines in cell therapy workflows

Cytiva: Vertical integration to streamline purification and quality assurance processes

Lonza: Local manufacturing hubs to de-risk supply chain dependencies in North America

Key gmp cytokines Companies10 items

Bio-Techne

PeproTech

CellGenix

Miltenyi Biotec

Cytiva

Lonza

ReproCELL

Sino Biological

Akron Biotech

Creative Bioarray

Market Ecosystem

Raw material/component suppliers — provide starting biological materials, growth factors, and reagents for cytokine production

Cytokine manufacturers — produce GMP-compliant cytokines using cell culture, fermentation, and purification systems

Technology providers — supply bioreactors, analytical instruments, and software for process control and quality assurance

Contract development and manufacturing organizations (CDMOs) — support scale-up, validation, and bulk production of cytokines

Distributors/logistics partners — manage cold chain storage, transportation, and traceability of temperature-sensitive products

Biopharmaceutical companies — integrate cytokines into drug discovery, cell therapy, and vaccine development pipelines

Regulatory bodies — enforce GMP standards, oversee facility audits, and validate product safety and efficacy profiles

Recent Industry Insights

Analyst Overview

Table of Contents